

FREMANEZUMAB injection (Ajovy® ▼) for prevention of migraine

The Pan Mersey Area Prescribing Committee recommends the prescribing of FREMANEZUMAB injection (Ajovy® ▼), by specialists only, for prevention of migraine in accordance with NICE TA631.

RED

Fremanezumab is licensed for prophylaxis of migraine in adults who have at least 4 migraine days per month.¹

NICE technology appraisal TA631² (3 June 2020) recommends fremanezumab (Ajovy® ▼) as an option for preventing migraine in adults, only if:

- > the migraine is chronic, that is, 15 or more headache days a month for more than 3 months with at least 8 of those having features of migraine
- > at least 3 preventive drug treatments have failed and
- > the company provides it according to the commercial arrangement

Treatment should be initiated by a specialist experienced in the diagnosis and treatment of migraine. Prescribing should be retained by the specialist.

Fremanezumab should be stopped if migraine frequency does not reduce by at least 30% after 12 weeks of treatment.²

For further information on the prevention of migraine, please refer to the following national and local guidance:

- > NICE Clinical Guideline [CG150] [Headaches in over 12s: diagnosis and management](#), updated November 2015.
- > British Association for the Study of Headache [National Headache Management System for Adults](#), 2019.
- > Pan Mersey Area Prescribing Committee [Headache pathway \(adults\)](#), last updated 26 June 2019.

NICE estimates the resource impact of implementing this guidance to be £8,263 per 100,000 population in 2020/21, rising to £15,755 per 100,000 population in 2024/25.

References

1. Teva UK Limited. Summary of Product Characteristics: [Ajovy \(fremanezumab\) 225mg pre-filled syringe for injection](#), 28 November 2020. Accessed 20 June 2020.
2. National Institute for Health and Care Excellence. Technology appraisal guidance: [Fremazenzumab for preventing migraine](#), 03 June 2020. Accessed 20 June 2020.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.